Related Experiment Video
Updated: Aug 14, 2026

Prehospital Thrombolysis: A Manual from Berlin
Published on: November 26, 2013
Controlled trials comparing reteplase with alteplase and streptokinase in patients with acute myocardial infarction
1Department of Medicine, School of Medicine, University of California, Davis, USA.
Although the ability of a thrombolytic agent to lyse a clot has been recognized for over 50 years, it was not until recently that this form of therapy was used to treat acute myocardial infarction. The need for rapid diagnosis and timely treatment to provide optimum outcomes and prognosis is now well established. Numerous clinical trials continue to examine alternative therapeutic regimens as well as the efficacy and safety of new agents to improve short- and long-term outcomes further. Reteplase is a new recombinant tissue-type plasminogen activator with potential advantages over currently available agents.
Although the ability of a thrombolytic agent to lyse a clot has been recognized for over 50 years, it was not until recently that this form of therapy was used to treat acute myocardial infarction. The need for rapid diagnosis and timely treatment to provide optimum outcomes and prognosis is now well established. Numerous clinical trials continue to examine alternative therapeutic regimens as well as the efficacy and safety of new agents to improve short- and long-term outcomes further. Reteplase is a new recombinant tissue-type plasminogen activator with potential advantages over currently available agents.
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome III: Diagnostic Studies

